Call: 860-258-3470


A Cancer Screening Test for Asymptomatic Individuals

Cancer screening is an effective way to detect cancer early when it can most easily be treated. Unfortunately, many people today are not being screened in line with recommendations.

Guardant Health is addressing this shortcoming by developing LUNAR-2, a blood test that seeks to increase screening rates and overcome the challenges of current methods, all from a simple blood draw.

To accomplish these objectives, Guardant Health is leveraging data from the tens of thousands of cancer patients it has already tested, as well as collaborating with multiple investigators at cancer centers around the world.

LUNAR-2’s first clinical study is in colorectal cancer (CRC), where today 1 in 3 adults are not getting the recommended screening.

Guardant Health believes a simple blood test can improve these rates by overcoming the barriers associated with available methods, including colonoscopy and stool-based testing, which while effective are time-consuming and invasive-resulting in screening rates below the Centers for Disease Control and Prevention’s goal of 80%.


Inclusion Criteria

Exclusion Criteria

About Guardant Health

This study is offered through Guardant Health – a leading precision oncology company dedicated to helping to conquer cancer throughout proprietary blood tests, vast data set, and advanced analytics. 

To Learn More

To learn more about participating as a Starling patient, please contact:

Kristine Calabrese

Clinical Research Coordinator

(860) 224-6266 x6616